Your browser doesn't support javascript.
loading
A distinct core regulatory module enforces oncogene expression in KMT2A-rearranged leukemia.
Harada, Taku; Heshmati, Yaser; Kalfon, Jérémie; Perez, Monika W; Xavier Ferrucio, Juliana; Ewers, Jazmin; Hubbell Engler, Benjamin; Kossenkov, Andrew; Ellegast, Jana M; Yi, Joanna S; Bowker, Allyson; Zhu, Qian; Eagle, Kenneth; Liu, Tianxin; Kai, Yan; Dempster, Joshua M; Kugener, Guillaume; Wickramasinghe, Jayamanna; Herbert, Zachary T; Li, Charles H; Vrabic Koren, Jost; Weinstock, David M; Paralkar, Vikram R; Nabet, Behnam; Lin, Charles Y; Dharia, Neekesh V; Stegmaier, Kimberly; Orkin, Stuart H; Pimkin, Maxim.
Affiliation
  • Harada T; Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
  • Heshmati Y; Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
  • Kalfon J; Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts 02142, USA.
  • Perez MW; Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
  • Xavier Ferrucio J; Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
  • Ewers J; Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
  • Hubbell Engler B; Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
  • Kossenkov A; The Wistar Institute, Philadelphia, Pennsylvania 19104, USA.
  • Ellegast JM; Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
  • Yi JS; Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts 02142, USA.
  • Bowker A; Baylor College of Medicine, Houston, Texas 77030, USA.
  • Zhu Q; Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
  • Eagle K; Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
  • Liu T; Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
  • Kai Y; Ken Eagle Consulting, Houston, Texas 77494, USA.
  • Dempster JM; Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
  • Kugener G; Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
  • Wickramasinghe J; Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts 02142, USA.
  • Herbert ZT; Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts 02142, USA.
  • Li CH; The Wistar Institute, Philadelphia, Pennsylvania 19104, USA.
  • Vrabic Koren J; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02215, USA.
  • Weinstock DM; Whitehead Institute for Biomedical Research, Cambridge, Massachusetts 02142, USA.
  • Paralkar VR; Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA.
  • Nabet B; Baylor College of Medicine, Houston, Texas 77030, USA.
  • Lin CY; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02215, USA.
  • Dharia NV; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
  • Stegmaier K; Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA.
  • Orkin SH; Baylor College of Medicine, Houston, Texas 77030, USA.
  • Pimkin M; Cancer and Blood Disorders Center, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
Genes Dev ; 36(5-6): 368-389, 2022 03 01.
Article in En | MEDLINE | ID: mdl-35301220
Acute myeloid leukemia with KMT2A (MLL) rearrangements is characterized by specific patterns of gene expression and enhancer architecture, implying unique core transcriptional regulatory circuitry. Here, we identified the transcription factors MEF2D and IRF8 as selective transcriptional dependencies of KMT2A-rearranged AML, where MEF2D displays partially redundant functions with its paralog, MEF2C. Rapid transcription factor degradation followed by measurements of genome-wide transcription rates and superresolution microscopy revealed that MEF2D and IRF8 form a distinct core regulatory module with a narrow direct transcriptional program that includes activation of the key oncogenes MYC, HOXA9, and BCL2. Our study illustrates a mechanism of context-specific transcriptional addiction whereby a specific AML subclass depends on a highly specialized core regulatory module to directly enforce expression of common leukemia oncogenes.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Myeloid-Lymphoid Leukemia Protein Type of study: Prognostic_studies Limits: Humans Language: En Year: 2022 Type: Article

Full text: 1 Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Myeloid-Lymphoid Leukemia Protein Type of study: Prognostic_studies Limits: Humans Language: En Year: 2022 Type: Article